ClinicalTrials.gg
TerminatedNCT06635135VENTURA-5Updated Jun 8, 2026Results posted

A Study of Aticaprant Plus an Antidepressant to Prevent Return of Depression Symptoms in Participants With Major Depressive Disorder Who Experience a Loss of Interest and Pleasure

A Phase 3 interventional study of Aticaprant and Placebo in Depressive Disorder, Major and Anhedonia, sponsored by Janssen Research & Development, LLC. Terminated at 95 sites in 13 countries. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-06-08.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Why this study was terminated
Early study termination due to insufficient efficacy.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
47
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 59 studies in Depressive Disorder, Major by Johnson & Johnson — 5 open to participants now, 5 under way, 5 of them phase 3. Depressive Disorder, Major · Johnson & Johnson.

Enrollment
44th of 52
47 · median 203
Started
2024
with 4 others
Phase 3
23 of 59
5 open now
Registered
54th of 59
by date

Among the 59 studies in Depressive Disorder, Major by Johnson & Johnson, this one is the 44th largest by enrollment of the 52 interventional ones that give a count, is one of 5 that started in 2024, is one of 23 in phase 3, and was the 54th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

5 of the 59 studies in Depressive Disorder, Major by Johnson & Johnson are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Depressive Disorder, Major by Johnson & Johnson, or all of them as a file.
02

Study summary

The purpose of this study is to assess how well aticaprant works compared to placebo when given in addition to antidepressant therapy (selective serotonin reuptake inhibitor [SSRI] or serotonin-norepinephrine reuptake inhibitor [SNRI]) in preventing return of depression symptoms in participants with major depressive disorder who experience a loss of interest and pleasure and who achieve a stable response after treatment with adjunctive aticaprant.

03

Conditions studied

  • Depressive Disorder, Major
  • Anhedonia
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be medically stable based on physical examination (including a brief neurologic examination), medical history, vital signs (including blood pressure), and 12-lead (ECG) performed at screening and OL baseline
  • Be medically stable based on clinical laboratory tests performed at screening
  • Meet diagnostic criteria for recurrent or single episode MDD, without psychotic features upon clinical assessment and confirmed by the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders-5th Edition (DSM-5) Axis I Disorders-Clinical Trials version (SCID-CT)
  • Have symptoms of anhedonia based on clinical assessment and confirmed by presence of anhedonia (positive response to major depressive episode (MDE) module symptom Item 2) on the SCID-CT at screening

Exclusion criteria

Exclusion Criteria:

  • Has had no response to 2 or more consecutive antidepressant treatments administered at adequate dose and duration in the current episode of depression including the current selective SSRI/SNRI assessed using the Massachusetts General Hospital Antidepressant Treatment Response Questionnaire (MGH ATRQ)
  • Has a history or evidence of noncompliance with current antidepressant therapy
  • Has a history of moderate-to-severe substance use disorder including alcohol use disorder according to criteria within 6 months before screening
  • Has homicidal ideation/intent, per the investigator's clinical judgment, or has suicidal ideation with some intent to act within 3 months prior to the start of the screening phase
  • Has cognitive impairment per investigator judgment that would render the invalid or limit the ability of the participant to comply with the study requirements
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
47 participants (actual)

Study arms

  • Experimental
    Aticaprant

    Drug: Aticaprant

  • Placebo comparator
    Placebo

    Other: Placebo

Interventions

  • Aticaprant will be administered orally.

    Also known as: JNJ-67953964

  • OtherPlacebo

    Placebo will be administered orally.

06

What researchers measure

Primary outcomes

  1. Time From Randomization Into Double Blind (DB) Treatment Maintenance Phase to the First Documentation of Relapse

    Relapse is defined as any of the following: MADRS total score \>=22 for 2 consecutive assessments separated by 7 (+/-3) days and/or hospitalization or observation for worsening depression, or any clinically relevant event per clinical judgment suggestive of relapse of depressive illness, such as active suicidal ideation with intent or evidence of suicidal behavior based on the Columbia-Suicide Severity Rating Scale (C-SSRS), suicide attempt, completed suicide, or hospitalization for suicide prevention. Relapse date is defined by the second MADRS assessment. MADRS is a clinician-rated 10-item scale scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms), with higher scores indicating more severe symptoms. C-SSRS is clinician-rated and reports severity and frequency of suicide-related ideation and behavior, categorized as no ideation/behavior (0), suicidal ideation (1 -5), or suicidal behavior (6 -10), with higher scores reflecting greater severity.

    Time frame: From date of DB randomization (Day 113) up to first documentation of relapse (up to early termination of study [Day 140])

07

Results

Posted Jun 8, 2026
Limitations and caveats
As study terminated early, primary and secondary efficacy endpoint analyses specified in the protocol were not conducted as per the statistical analysis plan. No subject was randomised to placebo, results for only the DB aticaprant arm are presented.

Participant flow

Adult subjects who had major depressive disorder (MDD) with moderate-to-severe anhedonia (ANH+) and an inadequate response to an ongoing antidepressant therapy were treated. Study was conducted in 3 phases: Open label (OL) initial treatment phase (IN), OL treatment stabilization (ST) phase and double blind (DB) treatment maintenance (TM) phase.

OL Initial Treatment Phase (Week 1-6)
Participant flow — OL Initial Treatment Phase (Week 1-6)
MilestoneOL (IN) Phase: Aticaprant 10 mgOL (ST) Phase: Aticaprant 10 mgDB Treatment Maintenance Phase: Aticaprant 10 mg
Started4700
Completed1900
Not completed2800
Withdrew: Adverse event100
Withdrew: Lack of efficacy100
Withdrew: Study terminated by sponsor2500
Withdrew: Withdrawal by subject100
OL Treatment ST Phase (From Week 7-16)
Participant flow — OL Treatment ST Phase (From Week 7-16)
MilestoneOL (IN) Phase: Aticaprant 10 mgOL (ST) Phase: Aticaprant 10 mgDB Treatment Maintenance Phase: Aticaprant 10 mg
Started0180
Completed020
Not completed0160
Withdrew: Study terminated by sponsor0140
Withdrew: Other010
Withdrew: Missing disposition information010
DB TM Phase (From Week 16-20)
Participant flow — DB TM Phase (From Week 16-20)
MilestoneOL (IN) Phase: Aticaprant 10 mgOL (ST) Phase: Aticaprant 10 mgDB Treatment Maintenance Phase: Aticaprant 10 mg
Started002
Completed000
Not completed002
Withdrew: Study terminated by sponsor002

Outcome measures

PrimaryTime From Randomization Into Double Blind (DB) Treatment Maintenance Phase to the First Documentation of Relapse

Relapse is defined as any of the following: MADRS total score \>=22 for 2 consecutive assessments separated by 7 (+/-3) days and/or hospitalization or observation for worsening depression, or any clinically relevant event per clinical judgment suggestive of relapse of depressive illness, such as active suicidal ideation with intent or evidence of suicidal behavior based on the Columbia-Suicide Severity Rating Scale (C-SSRS), suicide attempt, completed suicide, or hospitalization for suicide prevention. Relapse date is defined by the second MADRS assessment. MADRS is a clinician-rated 10-item scale scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms), with higher scores indicating more severe symptoms. C-SSRS is clinician-rated and reports severity and frequency of suicide-related ideation and behavior, categorized as no ideation/behavior (0), suicidal ideation (1 -5), or suicidal behavior (6 -10), with higher scores reflecting greater severity.

Time frame:
From date of DB randomization (Day 113) up to first documentation of relapse (up to early termination of study [Day 140])
Reported as:
Median · days
Time From Randomization Into Double Blind (DB) Treatment Maintenance Phase to the First Documentation of Relapse
daysDB Treatment Maintenance Phase: Aticaprant 10 mg
Time From Randomization Into Double Blind (DB) Treatment Maintenance Phase to the First Documentation of RelapseNA (NA to NA)

Adverse events

Collected over OL (IN) Arm: From Day 1 up to Week 8; OL (ST) Arm: From Week 7 up to Week 18; DB (TM) Arm: From Week 16 up to Week 20. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
OL (IN) Phase: Aticaprant 10 mg0/47 (0%)0/47 (0%)13/47 (27.7%)
OL (ST) Phase: Aticaprant 10 mg0/18 (0%)0/18 (0%)5/18 (27.8%)
DB Treatment Maintenance Phase: Aticaprant 10 mg0/2 (0%)0/2 (0%)0/2 (0%)
Most frequent other events
Most frequent other events
EventOL (IN) Phase: Aticaprant 10 mgOL (ST) Phase: Aticaprant 10 mgDB Treatment Maintenance Phase: Aticaprant 10 mg
PruritusSkin and subcutaneous tissue disorders5/472/180/2
HeadacheNervous system disorders4/470/180/2
DiarrhoeaGastrointestinal disorders3/471/180/2
DyspepsiaGastrointestinal disorders3/470/180/2
InfluenzaInfections and infestations1/471/180/2
NasopharyngitisInfections and infestations1/471/180/2
Procedural PainInjury, poisoning and procedural complications0/471/180/2

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)OL (IN) Phase: Aticaprant 10 mg
<=18 years0
Between 18 and 65 years47
>=65 years0
Age, Continuous
Age, Continuous(years)OL (IN) Phase: Aticaprant 10 mg
Mean42.5 ± 12.58
Sex: Female, Male
Sex: Female, Male(Participants)OL (IN) Phase: Aticaprant 10 mg
Female35
Male12
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)OL (IN) Phase: Aticaprant 10 mg
Hispanic or Latino20
Not Hispanic or Latino25
Unknown or Not Reported2
Race (NIH/OMB)
Race (NIH/OMB)(Participants)OL (IN) Phase: Aticaprant 10 mg
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American2
White43
More than one race1
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)OL (IN) Phase: Aticaprant 10 mg
Argentina5
Brazil3
Bulgaria1
Germany4
Mexico7
Poland10
United States17
08

Study locations

95 sites
  • Preferred Research Partners
    Little Rock, Arkansas 72211, United States
  • Wake Research PRI Encino
    Encino, California 91316, United States
  • Wr Pri Llc
    Newport Beach, California 92660, United States
  • ATP Clinical Research
    Orange, California 92866, United States
  • Myndful Research
    Redlands, California 92373, United States
  • Artemis Institute for Clinical Research
    San Diego, California 92103, United States
  • UHC Research
    Doral, Florida 33178, United States
  • Pharmax Research Clinic Inc
    Miami, Florida 33126, United States
  • GTL Medical and Research Group
    Miami, Florida 33173, United States
  • International Research Associates, LLC
    Miami, Florida 33183, United States
  • Harmony Clinical Research Inc
    North Miami Beach, Florida 33162, United States
  • APG Research LLC
    Orlando, Florida 32803, United States
  • Interventional Psychiatry of Tampa Bay
    Tampa, Florida 33629, United States
  • Synexus Clinical Research US Inc
    Atlanta, Georgia 30328, United States
  • Chicago Research Center
    Chicago, Illinois 60634, United States
  • Psychiatric Medicine Associates LLC
    Skokie, Illinois 60076, United States
  • Continental Clinical Solutions
    Towson, Maryland 21204, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • University of Missouri Health Care
    Columbia, Missouri 65212, United States
  • IMA Clinical Research PC
    Albuquerque, New Mexico 87109, United States
  • Integrative Clinical Trials LLC
    Brooklyn, New York 11229, United States
  • Bioscience Research LLC
    Mount Kisco, New York 10549, United States
  • Patient Priority Clinical Sites LLC
    Cincinnati, Ohio 45215, United States
  • Insight Clinical Trials
    Independence, Ohio 44131, United States
  • Laureate Institute for Brain Research
    Tulsa, Oklahoma 74136, United States
  • Keystone Clinical Studies LLC
    Plymouth Meeting, Pennsylvania 19462, United States
  • Coastal Carolina Research Center
    North Charleston, South Carolina 29405, United States
  • InSite Clinical Research LLC
    DeSoto, Texas 75115, United States
  • Earle Research
    Friendswood, Texas 77546, United States
  • Alpine Research Organization
    Clinton, Utah 84015, United States
  • Elligo Integrated Research Sites Integrated Clinical Research LLC Integrated Psych
    St. George, Utah 84770, United States
  • Hospital Italiano de Buenos Aires
    Buenos Aires, C1199ABB, Argentina
  • Centro Medico Instituto Modelo de Neurologia y Neurorehabilitacion
    Córdoba, X5004FJF, Argentina
  • Anima
    Alken, 3570, Belgium
  • AZ Sint-Lucas
    Assebroek, 8310, Belgium
  • UZ Brussel
    Brussels, 1090, Belgium
  • AZ Oudenaarde
    Oudenaarde, 9700, Belgium
  • Vitaz
    Sint-Niklaas, 9100, Belgium
  • CAEP Centro Avancado De Estudos E Pesquisas
    Campinas, 13087 567, Brazil
  • Centro Integrado Facili
    São Bernardo do Campo, 09726 150, Brazil
  • Mental Health Center - Rousse
    Rousse, 7003, Bulgaria
  • Medical Centre Akademika EOOD
    Sofia, 1000, Bulgaria
  • DCC 'Sv. Vrach and Sv. Sv. Kuzma and Damyan', OOD
    Sofia, 1408, Bulgaria
  • Diagnostic Consulting Center Mladost - M Varna
    Varna, 9020, Bulgaria
  • Mental Health Center - Vratsa EOOD
    Vratsa, 3000, Bulgaria
  • CHRU Besancon Hopital Jean Minjoz
    Besançon, 25000, France
  • Hopital la Colombiere
    Montpellier, 34090, France
  • CHU de Nantes hotel Dieu
    Nantes, 44093, France
  • CHS du Rouvray
    Sotteville-lès-Rouen, 76300, France
  • Hopital Sainte Musse
    Toulon, 83200, France
  • Klinische Forschung Berlin-Mitte GmbH
    Berlin, 10117, Germany
  • Praxis Dr. med. Kirsten Hahn
    Berlin, 13187, Germany
  • Pharmakologisches Studienzentrum Chemnitz GmbH
    Chemnitz, 09111, Germany
  • Universitatsklinikum Frankfurt
    Frankfurt am Main, 60528, Germany
  • Klinische Forschung Hamburg
    Hamburg, 20253, Germany
  • Oberhavel Kliniken GmbH
    Hennigsdorf, 16761, Germany
  • Universitaetsklinikum Muenster
    Münster, 48149, Germany
  • Boehm Peters Praxis fur Psychiatrie Psychotherapie Neurologie PartGmbB
    Rosenheim, 83022, Germany
  • Klinische Forschung Schwerin GmbH
    Schwerin, 19055, Germany
  • Eginitio Hospital
    Athens, 115 28, Greece
  • Attikon University General Hospital of Attica
    Athens, 124 62, Greece
  • University Hospital of Heraklion
    Heraklion, 715 00, Greece
  • University General Hospital of Ioannina
    Ioannina, 45110, Greece
  • G Papanikolaou Hospital of Thessaloniki
    Thessaloniki, 570 10, Greece
  • Hospital Aranda de la Parra S A de C V
    León, 37000, Mexico
  • Ketamine Mexico S de RL de C V
    Mexico City, 04100, Mexico
  • Human Science Research Trials S de RL de CV
    México, 14050, Mexico
  • cit NEUROPSIQUE
    Monterrey, 64610, Mexico
  • Osrodek Badan Klinicznych CLINSANTE S C Ewa Galczak Nowak Malgorzata Trzaska
    Bydgoszcz, 85 794, Poland
  • NZOZ Euromedica Grudziadz
    Grudziądz, 86 300, Poland
  • Niepubliczny Zaklad Opieki Psychiatrycznej MENTIS
    Leszno, 64-100, Poland
  • Centrum Medyczne Luxmed Sp z o o
    Lublin, 20 109, Poland
  • Praktyka Lekarska dr n med Malgorzata Wojtanowska Bogacka
    Poznan, 60 192, Poland
  • Indywidualna Specjalistyczna Praktyka Lekarska Agnieszka Remlinger Molenda
    Suchy Las, 62-002, Poland
  • Care Access Warszawa
    Warsaw, 00 719, Poland
  • Szpital Nowowiejski Osrodek Badan Klinicznych
    Warsaw, 00-774, Poland
  • MTZ Clinical Research Powered by Pratia
    Warsaw, 02-172, Poland
  • Centrum Zdrowia Mosty
    Wroclaw, 50 302, Poland
  • Spitalul Clinic de Psihiatrie Prof Dr Alexandru Obregia
    Bucharest, 041914, Romania
  • Centrul de Evaluarea si Tratament al Toxicodependentelor pentru Tineri Sf. Stelian
    Bucharest, 60222, Romania
  • Centrul Medical Melchisedec
    Craiova, 200157, Romania
  • Spitalul Clinic de Neuropsihiatrie
    Craiova, 200473, Romania
  • CMI Dr. Sarpe Marcel-Claudiu
    Focşani, 620117, Romania
  • Spitalul De Psihiatrie Elisabeta Doamna Galaţi
    Galați, 800179, Romania
  • Spitalul Clinic De Psihiatrie Doctor Gheorghe Preda
    Sibiu, 550082, Romania
  • Hosp. Univ. de Basurto
    Bilbao, 48013, Spain
  • Hosp Reina Sofia
    Córdoba, 14004, Spain
  • Hosp. Univ. Virgen de Las Nieves
    Granada, 18014, Spain
  • Hosp. Univ. La Paz
    Madrid, 28046, Spain
  • Hosp Virgen de La Victoria
    Málaga, 29010, Spain
  • Hosp. Univ. Son Espases
    Palma, 07120, Spain
  • Clinica Univ. de Navarra
    Pamplona, 31008, Spain
  • Hosp. El Bierzo
    Ponferrada, 24404, Spain
  • Hosp. Royo Villanova
    Zaragoza, 50015, Spain
  • Erenkoy Mental Health Hospital
    Istanbul, 34736, Turkey (Türkiye)
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · www.janssen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2024 to primary completion in Apr 2025, 6 months.

Results were first posted in Jun 2026, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2024
First posted
Oct 10, 2024
StartActual
Sep 19, 2024
Primary completionActual
Apr 9, 2025
CompletionActual
Apr 25, 2025
Results first posted
Jun 8, 2026
Last update
Jun 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06635135
Responsible party
Sponsor
First posted
Oct 10, 2024
Start date
Sep 19, 2024
Primary completion
Apr 9, 2025
Completion
Apr 25, 2025
Results posted
Jun 8, 2026
Last update
Jun 8, 2026

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aticaprant

Start the discussion